# Table of Contents

Supplementary Materials	1
Additional Methods	2
Danish Registries	2
Outcomes	2
Model Description	2
Validation and Evaluation	3
Additional Figures and Tables	6
ST1: Features overview.	6
ST2: Additional metrics for the validation.	7
ST3: Model comparison.	8
ST4: Kaplan Meier curve comparison of top risk quantiles between our prediction and age-sex alone.	is 9
ST5: Performance comparison to QCancer	10
ST6: Screening evaluation	11
ST7: Baseline risk comparison to Age-sex model on the UK Biobank	13
ST8: Proportional hazards assumption for the overall predictor.	14
SF1: Age-sex adjusted concordance for the development data.	15
SFC-X: Summary plots	15
SFC1: Oesophagus	16
SFC2: Stomach	17
SFC3: Colorectal	18
SFC4: Liver	19
SFC5: Pancreas	20
SFC6: Lung	21
SFC7: Melanoma	22
SFC8: Breast	23
SFC9: Cervix Uteri	24
SFC10: Corpus Uteri	25
SFC11: Ovary	26
SFC12: Prostate	27
SFC13: Testis	28
SFC14: Kidney	29
SFC15: Bladder	30
SFC16: Brain	31
SFC17: Thyroid	32
SFC18: Non-hodgkin lymphoma	33
SFC19: Multiple Myeloma	34
SFC20: AML	35

# **Supplementary Materials**

# Additional Methods

# **Danish Registries**

All registers are linkable through a unique personal identification number provided in the Central Person Registry (CPR). We use the Danish National Patients Registry (DNPR) <sup>65</sup>, a nationwide longitudinal register with data on hospital admissions (secondary care) across all of Denmark since 1977, to extract information on individual diagnoses. The Danish Register of Causes of Death (DR) <sup>66</sup>, covering all citizens dying in Denmark since 1970, and the Danish Cancer Register (CR) <sup>67</sup>, collating cancer incidence across the Danish population from 1978 onwards, are used to supplement the information in the DNPR. Additionally, we have been using the BigTempHealth project to extract information about basic health factors through doctor notes from hospitals in Region Zealand and the Capital Region since September, 2004.

# Outcomes

As mentioned in the main text, we focus on 20 major organ sites along with the groupings in NORDCAN <sup>56</sup> including: Oesophagus (C15), Stomach (C16), Colorectal (C18-21), Liver (C22), Pancreas (C25), Lung (C33-34), Melanoma (C43), Kidney (C64), Bladder (C67), Brain (C71), Thyroid (C73), Non-Hodgkin Lymphoma (C82-86), Multiple Myeloma (C90), AML (C\*- 920, 924, 925, 926, 928, 930, 940, 942) for both sexes. Female-only cancers include: Breast (C50), Cervix Uteri (C53), Corpus Uteri (C54), and Ovary (C56). Male-only cancers include: Prostate (C61), Testis (C62).

Cancers are identified by an entry in either the DNPR (primary + secondary diagnosis), CR, or DR. If multiple cancers are reported within a 3-month time window, all the corresponding cancers in the time window are considered equally valid as the primary.

For cancers reported in the CR, we check the morphological codes for benign, in situ, and metastatic cancers which are considered invalid.

The 20 major organ sites are preferentially treated to the bag-of-cancer and death outcome. If multiple cancers are considered, the earliest date is used for both.

# Model Description

As mentioned we make use of the method developed in <sup>60</sup>. However, as there are 20 different cancer types of interest + 2 additional composite outcomes, we expand the approach to account for competing risks.

We fit 22 cause-specific Cox models on the development-train set of the Danish registries, censoring individuals when they transition to a competing state. The validate set is used to gauge some of the hyperparameters and for initial model evaluation and sensitivity assessment. The test set has not been part of any model derivation and is solely used for final model evaluations.

for an event k can be written under the cox model as  $\$  as  $\$  applies a parameters  $A_{top} = a p a_{0k}(t) exp big[ boldsymbol{theta}_k^{top} mathbf{X}(t) big] $$, where $$ theta $$ are the model parameters and $$X(t) $$ are the time-varying covariates. The cause-specific cumulative hazard follows as $${A_k(t) = int_0^t alpha_k(u) textrm{d}u}$$ and is estimated via Breslow's estimator <sup>61</sup>. The overall survival function from any of the possible competing causes follows as $$S(t) = expbig[-\sum_{k=1}^{22} A_k(t) big]$$. We can then define the cumulative incidence function (CIF) as $${F_k(t) = int_0^t alpha_k(u)S(u) textrm{d}u}$$, incorporating the cause-specific hazards for each of the 22 event types <sup>68</sup>. The CIF forms the basis for most of your predictions. It should be noted that survival probabilities with internal time-varying covariates are ill-defined; we do assume here for simplicity that covariates stay constant over the prediction horizon.$ 

For the final model specification, we used a StudentT(loc=0, scale=0.01) distribution with 1.5 degrees of freedom as prior and a lower rank(50) Multivariate-Normal distribution as the distributional family for stochastic variational inference. Overall, we use a batch size of 720 randomly selected individuals with a 1/20 ratio between events and non-events for each stochastic gradient descent update.

# Validation and Evaluation

In total, we compared 6 different settings per cancer. The full model prediction is compared to an age-sex model based on the estimates from Denmark. A similar evaluation but now with an age-sex model (age up to a quadratic term and interactions) fitted on the UK Biobank data itself. We assessed the compatibility of the age-sex models and generally, the models perform similarly based on the ROC-AUC. Additionally, we evaluated Spearman's rank correlation between the two scores and almost all show a  $\$  except for Breast (0.62), Thyroid (0.74), and Melanoma (0.84) (supplementary table 7).

Testis and Cervix Uteri show a reversed correlation indicating a particular discordance between the underlying incidence curves.

Additionally, we evaluated the model improvements for incorporating the family history data and/or the health data (disease + basic health) individually. The combined predictor is assessed for the proportional hazards assumption (supplementary table 8). Further, we stratify individuals based on their predicted risk of the top 1% quantile and assess the corresponding Kaplan-Meier (KM) curve. The KM curve is then compared to a corresponding age-sex-based stratification. We use the additionally fitted age-sex model for the UK Biobank. Differences between the KM curves are assessed through a simple Cox regression (Hazard Ratio) and Log-Rank tests (supplementary table 4, supplementary figure C1-20e). Calibration of our predictions is assessed for each decentile of the risk score.



#### TRIPOD Checklist: Prediction Model Development

Section/Topic	Item	Checklist Item	Page
Title and abstract			
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	p.1
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	p. 2
Introduction			
Background and objectives	За	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	p. 3-4
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	p. 3
Methods			
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	p.4-5 24
Source of data	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	p. 4 fig. 1t
	5а	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	p.4-5 24
Participants	5b	Describe eligibility criteria for participants.	p. 5 fig. 1t
	5c	Give details of treatments received, if relevant.	-
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	p.6 p. 24
	6b	Report any actions to blind assessment of the outcome to be predicted.	p. 6
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	p.5-6 s. tab.
Frediciors	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	p. 6
Sample size	8	Explain how the study size was arrived at.	p.5 fig. 1t
Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	p.5-6 s. tab.
Statistical	10a	Describe how predictors were handled in the analyses.	p.5-6 p. 25 s. tab.
analysis methods	10b	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	p.5-7
	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	p.6-7 p.25
Risk groups	11	Provide details on how risk groups were created, if done.	p.6-7 p.25
Results		·	p.20
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	p. 5 fig. 1t
Participants	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	tab. 1
Model	14a	Specify the number of participants and outcome events in each analysis.	tab. 1
development	14b	If done, report the unadjusted association between each candidate predictor and outcome.	online m.

Model	15a	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	online m.
specification	15b	Explain how to the use the prediction model.	online m.
Model performance	16	Report performance measures (with CIs) for the prediction model.	p.7-10 fig 1
Discussion			
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	p. 10-11
Interpretation	19b	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	p. 10-11
Implications	20	Discuss the potential clinical use of the model and implications for future research.	p. 10-11
Other information	ı		
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	p.12
Funding	22	Give the source of funding and the role of the funders for the present study.	p.2

We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

# Additional Figures and Tables

**ST1:** Features overview.

Category	Variable	Count	Encoding	Missingness	Transformations	Data So Danish Registries		Definition
Disease codes:						2 amon regionles	CA DIODAILE	
	Certain conditions originating in the	59	binary - (0, 1)			DNPR	Cat.: 1712	A total of 1305 diseases corresponding to ICD-10 3rd level codes from chapters 1-18 (excluding C*
	perinatal period Certain infectious and	173	binary - (0, 1)			DNPR	Cat.: 1712	are extracted from the DNPR (primary and secondary diagnoses only) and coded as binary
	parasitic diseases Congenital malformations,	87	binary - (0, 1)			DNPR	Cat.: 1712	indicators (0, 1), representing whether an individual ever had the disease by a given point i time. Diagnoses before 1995 were encoded in ICD-8 and have been transformed to ICD-10
	deformations and chromosomal abnormalities Diseases of the blood	34	binary - (0, 1)			DNPR	Cat.: 1712	based on previously used mappings. We rely on category 1712 for the external validation in the UKB, which is a composite of hospital admission records, primary care records, and self-reported
	and blood-forming organs and certain disorders involving the immune mechanism	34	unary - (0, 1)			UNER	Gal. 1712	diseases. The chapters 'Neoplasm' and 'Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified' are adapted from category 2000 (Hospital Episodes)
	Diseases of the circulatory system	77	binary - (0, 1)			DNPR	Cat.: 1712	as they are not provided in the other category.
	Diseases of the digestive system	72	binary - (0, 1)			DNPR	Cat.: 1712	
	Diseases of the ear and mastoid process	24	binary - (0, 1)			DNPR	Cat.: 1712	
	Diseases of the eye and adnexa	47	binary - (0, 1)			DNPR	Cat.: 1712	
	Diseases of the genitourinary system	82	binary - (0, 1)			DNPR	Cat.: 1712	
	Diseases of the musculoskeletal system and connective tissue	79	binary - (0, 1)			DNPR	Cat.: 1712	
	Diseases of the nervous system	68	binary - (0, 1)			DNPR	Cat.: 1712	
	Diseases of the respiratory system	64	binary - (0, 1)			DNPR	Cat.: 1712	
	Diseases of the skin and subcutaneous tissue	72	binary - (0, 1)			DNPR	Cat.: 1712	
	Endocrine, nutritional and metabolic diseases	74	binary - (0, 1)			DNPR	Cat.: 1712	
	Mental and behavioural disorders	78	binary - (0, 1)			DNPR	Cat.: 1712	
	Neoplasms Pregnancy, childbirth	48 76	binary - (0, 1) binary - (0, 1)			DNPR DNPR	Cat.: 2000 Cat.: 1712	
	and the puerperium							
	Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	91	binary - (0, 1)			DNPR	Cat.: 2000	
Senealogy:								
	Family case	20	categorical - (-1, 0, 1)	Effect coding: missing := 0		CPR, DNPR, CR, DR	Cat.: 20107, 20110, 20111	Genealogy information is computed for each individual based on information of up to 2nd- degree relatives (excluding the children of children). Families are reconstructed based on information on the father and mother from the
	Family case (1st degree relatives)	20	categorical - (-1, 0, 1)	Effect coding: missing := 0		CPR, DNPR, CR, DR	Cat.: 20107, 20110, 20111	CPR. Information on half-siblings is considered, while zygosity information for twins was not available. We use effect coding for the indicator and add a state indicating missingness. Effectively, -1 encodes no effect/not present, 0
	Early age (age <= 50 years)	20	categorical - (-1, 0, 1)	Effect coding: missing := 0		CPR, DNPR, CR, DR		encodes missingness (here: if there is no information on any of the parents), and 1 for effect/present.
	Family case			moonig o		5N		For the UKB analysis, we rely on categories 20107, 20110, and 20111. However, genealogy information is only provided for first-degree relatives with Prostate, Breast, Bowel, and Lung
	Multiple family cases	20	categorical - (-1, 0, 1)	Effect coding: missing := 0		CPR, DNPR, CR, DR	Cat.: 20107, 20110, 20111	cancers. For other cancers and the early cancer indicator, we set the covariates to 0, indicating insufficient information on family history.
Basic Health:								
	Alcoholic	1	categorical - (-1, 0, 1)	Effect coding: missing := 0		BTH, DNPR	Cat.: 1558	Indicator of "even had a problematic alcohol consumption", defined a setther directly noted in the doctor's notes, as drinking 20 units per veel reharding that an alcohol-related disease (F10', G621, G312, G721, H26, K70', K292, K860, 2764, Z721, No indication of an alcohol problem is coded as -1 if doctor notes are available, 00 dherwise. If evidence of an alcohol UKB wildration, we use the survey question table alcoholic consumption in Cat. 1559 with 'dataly' encoded as 1, "almost dataly' encoded as 0, and the rest encoded as -1.
	Smoking	1	categorical - (-1, 0, 1)	Effect coding: missing := 0		BTH, DNPR	Cat.: 20116	Indicator of "ever smoker" as mentioned in the doctor's notes or through codes (F17*, 2508, 2716, 2720). Similar coding as for alcoholic. Fo the UKB validation, we use the survey question about smoking behavior in Cat. 20116 with current or former smoker encoded as 1.
	High blood pressure	1	categorical - (-1, 0, 1)	Effect coding: missing := 0		BTH, DNPR	Cat.: 4079, 4080	Indicator of "ever had high blood pressure" as diastolic >=90 and systolic >=140 or (110-13, 115 Similar coding as for alcoholic. [Units in mm Hg]
	Low blood pressure	1	categorical - (-1, 0, 1)	Effect coding: missing := 0		BTH, DNPR	Cat.: 4079, 4080	Indicator of "ever had low blood pressure" as diastolic <=60 and systolic <=90 or (195). Simila coding as for alcoholic. [Units in mm Hg]
	Height	1	continuous (cm)	Single mean imputation: (165f, 177m).	centered : 170 scaled:100	ВТН	Cat.: 50	The height is extracted from the doctor's notes. Missing values are single imputed by the corresponding mean for the sex (165f, 177m).
	Weight	1	continuous (kg)	Single mean imputation: (69f, 82m).	centered : 75 scaled:100	втн	Cat.: 21002	The weight is extracted from the doctor's notes. Missing values are single imputed by the corresponding mean for the sex (69f, 82m).
	Age at first birth	1	continuous (years)		centered : - scaled:100	CPR, DNPR	Cat.: 2754	Age at first birth as extracted from the CPR (ID appears as the mother for someone else) or a child birth-related diagnosis in the DNPR (O81-

# **ST2:** Additional metrics for the validation.

	Cancer	Concordance	s.d.	AUC	Brier score
	Oesophagus	0.891	0.003	0.889	0.000
	Stomach	0.854	0.004	0.852	0.000
	Colorectal	0.846	0.001	0.845	0.002
	Liver	0.905	0.004	0.903	0.000
	Pancreas	0.859	0.003	0.857	0.000
	Lung	0.887	0.001	0.885	0.002
	Melanoma	0.702	0.003	0.703	0.001
	Breast	0.751	0.002	0.753	0.005
	Cervix Uteri	0.656	0.007	0.659	0.000
×	Corpus Uteri	0.850	0.003	0.849	0.001
narl	Ovary	0.787	0.005	0.786	0.001
Denmark	Prostate	0.890	0.001	0.890	0.004
	Testis	0.682	0.008	0.691	0.000
	Kidney	0.828	0.003	0.827	0.001
	Bladder	0.892	0.003	0.890	0.000
	Brain	0.752	0.006	0.751	0.000
	Thyroid	0.716	0.008	0.718	0.000
	Non-Hodgkin Lymphoma	0.794	0.004	0.793	0.001
	Multiple Myeloma	0.848	0.004	0.846	0.000
	AML	0.798	0.011	0.797	0.000
	Other	0.796	0.001	0.796	0.007
	Death	0.886	0.001	0.887	0.008
	Oesophagus	0.742	0.014	0.739	0.001
	Stomach	0.705	0.017	0.701	0.001
	Colorectal	0.657	0.007	0.654	0.004
	Liver	0.739	0.019	0.736	0.001
	Pancreas	0.667	0.014	0.663	0.001
	Lung	0.781	0.007	0.779	0.003
	Melanoma	0.573	0.011	0.570	0.002
	Breast	0.571	0.006	0.571	0.011
	Cervix Uteri	0.551	0.054	0.550	0.000
h	Corpus Uteri	0.623	0.015	0.622	0.002
UK Biobank	Ovary	0.577	0.017	0.576	0.001
Bi	Prostate	0.660	0.005	0.658	0.013
Ň	Testis	0.740	0.096	0.737	0.000
	Kidney	0.673	0.014	0.669	0.001
	Bladder	0.758	0.009	0.755	0.002
	Brain	0.587	0.019	0.584	0.001
	Thyroid	0.660	0.027	0.661	0.000
	Non-Hodgkin Lymphoma	0.643	0.012	0.639	0.001
	Multiple Myeloma	0.671	0.017	0.668	0.001
	AML	0.709	0.038	0.706	0.000
	Other	0.650	0.003	0.648	0.015
	Death	0.791	0.004	0.790	0.009

# ST3: Model comparison.

Cancer		Lo	g-Likelihood					P-Va	lues (FWER-Correc	ted)	
	Base	Base + Health	Base + Gene	All	UKB-AgeSex	Base / All	Base / Health	Base / Gene	Base+Health / All	Base+Gene / All	UKB-AgeSex / A
Oesophagus	-20326.662	-20097.864	-20321.159	-20093.123		0.000	0.000	0.021	0.046	0.000	
Stomach	-22039.178	-21991.113	-22033.892	-21985.542		0.000	0.000	0.025	0.019	0.000	
Colorectal	-153697.350	-153600.420	-153620.910	-153528.560		0.000	0.000	0.000	0.000	0.000	
Liver	-16547.177	-15631.003	-16546.814	-15629.177		0.000	0.000	0.901	0.560	0.000	
Pancreas	-30025.035	-29888.958	-30024.890	-29888.938		0.000	0.000	0.901	0.901	0.000	
Lung	-131119.800	-129100.720	-131063.150	-129041.780		0.000	0.000	0.000	0.000	0.000	
Melanoma	-82073.718	-81856.785	-81909.540	-81708.856		0.000	0.000	0.000	0.000	0.000	
Breast	-160303.310	-160080.800	-160140.350	-159937.230		0.000	0.000	0.000	0.000	0.000	
Cervix Uteri	-14084.641	-14029.227	-14052.087	-13996.080		0.000	0.000	0.000	0.000	0.000	
Corpus Uteri	-24088.914	-23882.060	-24087.109	-23881.203		0.000	0.000	0.574	0.901	0.000	
Ovary	-17526.526	-17523.697	-17524.498	-17522.032		0.179	0.238	0.485	0.635	0.316	
Prostate	-128125.440	-127932.410	-127910.540	-127718.150		0.000	0.000	0.000	0.000	0.000	
Testis	-14680.359	-14661.843	-14586.911	-14577.004		0.000	0.000	0.000	0.000	0.000	
Kidney	-31369.039	-31221.597	-31369.031	-31221.459		0.000	0.000	0.901	0.901	0.000	
Bladder	-24361.172	-24232.906	-24339.634	-24210.174		0.000	0.000	0.000	0.000	0.000	
Brain	-19830.430	-19707.512	-19828.016	-19705.472		0.000	0.000	0.336	0.477	0.000	
Thyroid	-15117.174	-15010.054	-15104.929	-14999.389		0.000	0.000	0.000	0.000	0.000	
Non-Hodgkin Lymphoma	-38351.686	-38285.587	-38350.698	-38284.298		0.000	0.000	0.901	0.867	0.000	
Multiple Myeloma	-14756.177	-14663.027	-14756.030	-14662.980		0.000	0.000	0.901	0.901	0.000	
AML	-6470.858	-6395.330	-6468.353	-6393.188		0.000	0.000	0.302	0.423	0.000	
Other	-415320.660	-414354.960	-415245.180	-414287.250		0.000	0.000	0.000	0.000	0.000	
Death	-542139.070	-521669.520	-542094.930	-521584.520		0.000	0.000	0.000	0.000	0.000	
Oesophagus	-3531.5363	-3503.0347	-3530.8549	-3502.4515	-3520.8277	0.000	0.000	1.000	1.000	0.000	0.000
Stomach	-2768.6624	-2758.5274	-2768.4287	-2758.3464	-2765.9961	0.002	0.000	1.000	1.000	0.001	0.027
Colorectal	-18342.54	-18307.128	-18330.719	-18294.988	-18338.608	0.000	0.000	0.000	0.000	0.000	0.000
Liver	-2374.805	-2321.8366	-2373.8003	-2320.9145	-2370.1542	0.000	0.000	1.000	1.000	0.000	0.000
Pancreas	-4453.0337	-4446.6233	-4452.7434	-4446.2871	-4450.3698	0.060	0.020	1.000	1.000	0.019	0.691
Lung	-13613.933	-13218.56	-13585.766	-13197.524	-13580.378	0.000	0.000	0.000	0.000	0.000	0.000
Melanoma	-8329.6242	-8325.2196	-8329.5261	-8325.1243	-8316.4255	0.522	0.147	1.000	1.000	0.147	1.000
Breast	-26872.947	-26840.228	-26839.827	-26808.835	-26866.537	0.000	0.000	0.000	0.000	0.000	0.000
Cervix Uteri	-390.77261	-389.71526	-390.211	-389.1597	-390.68294	1.000	1.000	1.000	1.000	1.000	1.000
Corpus Uteri	-4524.5095	-4486.6616	-4524.3545	-4486.4278	-4524.2196	0.000	0.000	1.000	1.000	0.000	0.000
Ovary	-3227.4494	-3226.7124	-3226.365	-3225.6125	-3225.0276	1.000	1.000	1.000	1.000	1.000	1.000
Prostate	-26920.688	-26910.062	-26893.111	-26882.965	-26896.436	0.000	0.000	0.000	0.000	0.000	0.000
Testis	-132.0101	-126.92288	-130.50462	-125.3686	-132.09463	0.067	0.073	1.000	1.000	0.069	0.061
Kidney	-4532.2661	-4526.9541	-4532.1961	-4526.8798	-4528.2026	0.224	0.058	1.000	1.000	0.058	1.000
Bladder	-7577.9878	-7559.3102	-7573.8966	-7555.19	-7562.0885	0.000	0.000	0.207	0.201	0.000	0.052
Brain	-2667.9257	-2667.5505	-2667.5118	-2667.1313	-2664.0967	1.000	1.000	1.000	1.000	1.000	1.000
Thyroid	-1196.4797	-1180.7691	-1195.4041	-1179.6977	-1187.8032	0.000	0.000	1.000	1.000	0.000	0.018
Non-Hodgkin Lymphoma	-6684.3819	-6670.0451	-6684.3571	-6670.0311	-6678.2122	0.000	0.000	1.000	1.000	0.000	0.017
Multiple Myeloma	-3113.8261	-3103.4745	-3113.8099	-3103.4495	-3109.174	0.002	0.000	1.000	1.000	0.000	0.160
AML	-711.75173	-684.64681	-711.72603	-684.60737	-710.47767	0.000	0.000	1.000	1.000	0.000	0.000
Other	-75270.965	-75222.28	-75268.819	-75220.573	-75232.146	0.000	0.000	0.980	1.000	0.000	0.001
Death	-42397.76	-40780.501	-42385.376	-40774.579	-42238.397	0.000	0.000	0.000	0.032	0.000	0.000

**ST4:** Kaplan Meier curve comparison of top risk quantiles between our predictions and age-sex alone.

			Denmark						UK B	iobank		
Cancer	Hazard Ratio (HR)	HR - lower	HR - upper	LogRank Statistic	P-Value	P-Value (FWER)	Hazard Ratio (HR)	HR - lower	HR - upper	LogRank Statistic	P-Value	P-Value (FWER
Oesophagus	1.974	1.566	2.489	34.435	0.000	0.000	2.623	1.096	6.281	5.063	0.024	0.391
Stomach	1.127	0.857	1.482	0.738	0.390	0.648	1.691	0.615	4.654	1.060	0.303	0.861
Colorectal	0.975	0.874	1.088	0.208	0.648	0.648	1.171	0.729	1.879	0.427	0.513	0.861
Liver	4.116	3.283	5.159	177.442	0.000	0.000	3.589	1.636	7.875	11.623	0.001	0.012
Pancreas	1.659	1.314	2.095	18.509	0.000	0.000	1.534	0.627	3.752	0.891	0.345	0.861
Lung	2.404	2.175	2.658	314.215	0.000	0.000	4.266	2.800	6.499	54.207	0.000	0.000
Melanoma	1.555	1.262	1.916	17.478	0.000	0.000	0.922	0.445	1.911	0.047	0.828	0.861
Breast	1.326	1.139	1.544	13.345	0.000	0.003	1.945	1.235	3.064	8.550	0.003	0.062
Cervix Uteri	1.196	0.589	2.426	0.246	0.620	0.648						
Corpus Uteri	2.615	1.941	3.521	43.207	0.000	0.000	6.895	2.385	19.938	17.174	0.000	0.001
Ovary	1.369	0.915	2.048	2.354	0.125	0.625	3.316	0.345	31.883	1.213	0.271	0.861
Prostate	1.255	1.117	1.409	14.803	0.000	0.001	1.287	0.854	1.938	1.463	0.226	0.861
Testis	1.909	1.144	3.185	6.349	0.012	0.081						
Kidney	1.567	1.212	2.025	11.978	0.001	0.005	1.253	0.519	3.024	0.253	0.615	0.861
Bladder	1.659	1.342	2.051	22.336	0.000	0.000	1.110	0.687	1.793	0.183	0.669	0.861
Brain	2.446	1.643	3.641	20.764	0.000	0.000	1.427	0.453	4.497	0.373	0.541	0.861
Thyroid	5.063	2.965	8.645	43.730	0.000	0.000	3.814	1.050	13.858	4.791	0.029	0.435
Non-Hodgkin Lymphoma	1.124	0.885	1.426	0.918	0.338	0.648	1.802	0.796	4.078	2.056	0.152	0.861
Multiple Myeloma	1.827	1.285	2.596	11.618	0.001	0.006	1.452	0.553	3.814	0.579	0.447	0.861
AML	1.585	1.062	2.366	5.166	0.023	0.138	4.068	0.864	19.156	3.702	0.054	0.707
Other	1.090	1.013	1.171	5.396	0.020	0.121	0.980	0.782	1.228	0.030	0.861	0.861
Death	3.292	3.156	3.433	3468.066	0.000	0.000	4.618	3.841	5.552	320.842	0.000	0.000

# **ST5:** Performance comparison to QCancer

Cancer	Ours - ROC-AUC	QCancer - F	ROC-AUC
		Female	Male
Oesophagus	0.889	0.863	0.856
Stomach	0.852		
Colorectal	0.845	0.841	0.851
Liver	0.903		
Pancreas	0.857	0.865	0.851
Lung	0.885	0.9	0.901
Melanoma	0.703		
Breast	0.753	0.747	
Cervix Uteri	0.659		
Corpus Uteri	0.849	0.818	
Ovary	0.786	0.764	
Prostate	0.890		0.794
Testis	0.691		
Kidney	0.827	0.849	0.856
Bladder	0.890		
Brain	0.751		
Thyroid	0.718		
Non-Hodgkin Lymphoma	0.793		
Multiple Myeloma	0.846		
AML	0.797	0.798	0.79
Other	0.796		
Death	0.887		

# **ST6:** Screening evaluation

	Age	N	Cancers	Age - mean	Age - s d	Baseline Age - g10	Age - n25	Age - median	Age - 075	Age - c90	N	Cancers				med scree Age - a25	Age - median	Age - n75	Age
Oesophagus	40	397,561	14	43.34	1.29	41.73	42.53	43.90	44.14	44.55	397,561	17	42.63	1.92	39.47	41.42	43.81	43.91	44.
Oesophagus	45	411,925	60	47.51	1.56	45.52	46.15	47.33	49.08	49.55	411,926	61	47.27	1.84	45.03	45.76	47.22	49.07	49.
Oesophagus	50	382,840	125	52.83	1.36	50.82	51.82	52.91	53.95	54.58	382,840	133	52.05	2.44	48.96	50.98	52.68	53.83	54.
	55	332,946	240	57.82	1.30	55.76	56.65	57.95	59.16	59.69	332,946	275	56.44	3.18	52.35	54.68	57.46	58.78	59.
Oesophagus	60	299,441	326	62.72	1.42	60.69	61.65	62.88	63.94	64.49	299,441	403	60.39	3.98	54.64	58.24	61.63	63.50	64.
Oesophagus Oesophagus	65	299,441	351	67.72	1.40	65.76	66.52	67.75	68.96	69.58	299,441	405	64.15	4.85	57.03	61.22	65.39	68.11	69
	40											486							
Stomach		397,561	37	42.85	1.43	40.69	41.67	43.32	43.90	44.60	397,561		42.40	1.82	39.52	40.98	43.13	43.84	44
Stomach	45 50	411,925 382.840	104 136	47.72 52.80	1.47	45.63 50.83	46.46 51.83	47.81 52.93	48.96 53.86	49.60 54.55	411,925 382.840	100	47.39 52.15	2.09	44.66 49.12	46.15 50.89	47.81	48.96 53.71	49
Stomach																			
Stomach	55	332,946	224	57.69	1.36	55.68	56.65	57.66	58.84	59.53	332,946	235	56.94	2.44	53.45	55.88	57.47	58.79	59
Stomach	60	299,441	297	62.60	1.47	60.43	61.35	62.71	63.94	64.47	299,441	317	61.87	2.43	58.47	60.37	62.41	63.83	64
Stomach	65	292,150	385	67.70	1.43	65.78	66.47	67.72	68.95	69.62	292,150	415	66.64	2.75	62.89	65.15	67.16	68.86	69
Colorectal	40	397,561	220	42.77	1.32	40.87	41.70	42.88	43.85	44.46	397,561	236	42.09	2.55	38.98	41.35	42.72	43.75	44
Colorectal	45	411,925	574	47.83	1.34	45.80	46.87	47.89	48.94	49.59	411,934	580	47.52	2.01	45.33	46.61	47.84	48.91	49
Colorectal	50	382,840	871	52.72	1.38	50.78	51.62	52.79	53.90	54.56	382,840	937	52.15	2.18	49.12	51.12	52.54	53.83	54
Colorectal	55	332,946	1,316	57.63	1.46	55.54	56.35	57.69	58.89	59.57	332,947	1,362	56.95	2.50	53.68	55.77	57.43	58.83	59
Colorectal	60	299,441	1,997	62.66	1.43	60.64	61.45	62.75	63.91	64.57	299,441	1,988	61.47	3.08	57.11	60.00	62.31	63.84	6
Colorectal	65	292,150	2,711	67.66	1.42	65.62	66.51	67.75	68.87	69.61	292,150	2,688	66.31	3.51	60.94	65.00	67.47	68.77	6
iver	40	397,561	15	42.88	1.56	41.08	41.66	42.79	44.42	44.86	397,563	16	42.35	2.53	40.50	41.51	42.62	44.32	4
iver	45	411,925	33	47.88	1.46	45.97	46.69	48.08	49.27	49.76	411,925	39	46.82	2.86	44.15	45.72	47.32	49.09	4
iver	50	382,840	94	53.02	1.36	51.18	51.94	53.03	54.29	54.76	382,840	112	51.86	3.16	47.53	50.93	52.70	54.09	5
iver	55	332,946	173	57.71	1.43	55.75	56.57	57.76	59.11	59.50	332,946	237	55.92	3.37	51.53	54.25	56.77	58.42	55
iver	60	299,441	235	62.61	1.46	60.73	61.21	62.78	63.80	64.66	299,441	374	59.64	4.22	53.67	57.27	60.60	63.03	6
iver	65	292,150	281	67.66	1.45	65.54	66.52	67.72	68.96	69.52	292,150	517	63.17	5.44	55.54	59.57	64.48	67.68	6
ancreas	40	397,561	39	42.97	1.26	41.10	42.03	43.27	44.09	44.52	397,561	38	42.72	2.05	41.06	41.95	43.28	44.11	4
ancreas	45	411,925	103	47.91	1.30	46.28	46.83	47.91	49.14	49.68	411,925	102	47.85	1.43	46.28	46.81	47.94	49.19	4
ancreas	50	382,840	175	52.67	1.39	50.75	51.65	52.64	54.00	54.64	382,840	187	52.02	2.26	48.26	50.95	52.40	53.81	54
ancreas	55	332,946	268	57.81	1.42	55.73	56.76	57.76	59.13	59.66	332,946	300	56.78	2.77	53.17	55.16	57.44	58.98	5
ancreas	60	299,441	370	62.68	1.39	60.74	61.50	62.80	63.87	64.57	299,441	402	61.41	3.15	57.55	59.91	62.16	63.76	6
ancreas	65	292,150	561	67.59	1.44	65.48	66.40	67.68	68.81	69.53	292,150	584	66.47	3.16	63.26	65.18	67.07	68.59	6
ung	40	397,561	86	43.00	1.40	40.74	42.11	43.30	44.03	44.76	397,561	95	42.30	2.22	39.19	40.64	43.16	43.99	4
ung	45	411,925	300	48.06	1.39	45.96	47.04	48.32	49.26	49.73	411,933	307	47.45	2.38	44.32	46.41	48.14	49.16	4
ung	50	382,840	713	52.75	1.42	50.68	51.53	52.91	53.97	54.57	382,840	785	51.67	2.68	48.08	50.03	52.42	53.83	5
ung	55	332,946	1,195	57.74	1.46	55.61	56.50	57.91	58.95	59.64	332,959	1,412	55.93	3.42	50.90	53.92	56.82	58.68	5
ung	60	299,441	1,861	62.64	1.43	60.64	61.44	62.72	63.88	64.54	299,441	2,243	60.85	3.48	56.07	59.06	61.70	63.52	6
ung	65	292,150	2,445	67.60	1.42	65.60	66.37	67.68	68.80	69.54	292,150	3,152	65.40	3.72	60.33	63.60	66.24	68.21	6
reast	40	192,944	886	42.77	1.40	40.68	41.67	42.82	43.99	44.66	192,944	916	42.44	1.94	39.80	41.41	42.77	43.91	4
reast	45	198,309	1,442	47.86	1.40	45.72	46.74	48.06	49.06	49.63	198,309	1,513	47.18	2.32	43.89	46.01	47.72	48.96	4
reast	50	184,578	1,561	52.32	1.46	50.43	51.05	52.13	53.63	54.45	184,578	1,709	50.41	3.20	46.05	48.49	50.75	53.08	5
reast	55	161.464	1.476	57.54	1.45	55.54	56.25	57.54	58.80	59.55	161,464	1,749	54.22	4.36	47.96	50.90	55.22	57.93	5
reast	60	147,139	1,880	62.48	1.45	60.48	61.23	62.45	63.71	64.53	147,139	1,981	57.72	5.31	49.55	53.98	58.98	62.10	6
reast	65	145,266	1,924	67.34	1.40	65.48	66.15	67.28	68.51	69.35	145,266	2,140	59.52	6.09	50.34	55.32	60.55	64.27	6
orpus Uteri	40	192.944	40	42.90	1.33	41.19	41.80	42.93	43.86	44.77	192,944	51	41.42	2.81	37.56	39.60	41.86	43.64	4
orpus Uteri	45	198,309	99	47.73	1.46	45.88	46.52	47.63	49.20	49.71	198,309	108	46.95	2.39	43.72	45.92	47.31	48.86	4
orpus Uteri	50	184,578	190	52.66	1.43	50.61	51.49	52.88	53.89	54.56	184,578	209	51.50	2.72	47.76	49.95	51.97	53.56	5
Corpus Uteri	55	161,464	272	57.56	1.45	55.49	56.32	57.72	58.73	59.51	161,464	331	55.77	3.26	51.25	53.59	56.67	58.35	5
Corpus Uteri	60	147,139	326	62.59	1.39	60.58	61.38	62.62	63.77	64.52	147,139	423	59.85	3.99	53.95	57.66	60.76	63.02	6
orpus Uteri	65	145,266	424	67.67	1.44	65.65	66.45	67.71	68.93	69.60	145,266	538	64.29	4.77	57.27	61.70	65.68	68.07	6
)vary	40	192,944	68	42.68	1.50	40.73	41.39	42.71	44.02	44.62	192,944	71	41.87	2.46	38.10	40.63	42.18	43.88	4
Dvary	45	198,309	105	47.89	1.48	45.63	46.74	48.09	49.06	49.79	198,309	113	46.69	2.74	42.09	44.84	47.83	48.75	4
)vary	50	184,578	119	52.66	1.42	50.56	51.57	52.75	53.92	54.50	184,578	133	50.60	3.06	46.63	48.42	51.16	53.05	5
)vary	55	161,464	164	57.57	1.44	55.56	56.22	57.59	58.74	59.46	161,464	164	55.29	3.81	49.15	52.74	56.18	58.35	5
Dvary	60	147,139	202	62.56	1.45	60.56	61.35	62.66	63.80	64.48	147,139	205	60.48	4.10	54.63	58.67	61.84	63.41	6
Dvary	65	145,266	269	67.57	1.45	65.58	66.43	67.64	68.80	69.54	145,266	274	66.11	3.32	61.85	64.80	66.88	68.56	6
Prostate	40	204,617	30	42.88	1.45	40.40	41.74	43.37	44.07	44.63	204,617	30	42.83	1.66	40.40	41.74	43.37	44.07	4
Prostate	40	213,616	163	48.09	1.33	45.91	47.42	43.37	49.05	49.64	213,619	168	47.92	1.57	45.71	47.13	43.37	49.00	4
rostate	50	198.262	572	52.92	1.39	50.83	51.85	53.19	54.14	54.59	198,262	590	52.71	1.71	50.34	51.69	53.09	54.10	5
					1.39			57.90					57.39						
Prostate	55	171,482	1,174	57.80	1.44	55.67	56.67		59.08	59.67	171,482	1,246		2.03	54.55	56.31 60.76	57.80 62.56	59.02 63.85	59
rostate	60	152,302	2,030	62.70		60.63	61.50	62.78	63.95	64.66	152,302	2,198	62.02	2.38	58.92				6
rostate	65	146,884	3,016	67.63	1.41	65.61	66.43	67.68	68.84	69.54	146,884	3,224	66.43	2.92	62.26	64.92	67.18	68.65	69
idney	40	397,561	81	42.62	1.50	40.60	41.35	42.77	43.89	44.66	397,561	92	41.88	2.49	38.90	40.60	42.29	43.80	4
lidney	45	411,925	174	47.79	1.41	45.72	46.69	47.85	49.05	49.63	411,930	193	46.88	2.98	42.90	46.08	47.62	48.83	4
idney	50	382,840	241	52.61	1.41	50.69	51.44	52.59	53.92	54.48	382,840	280	51.42	3.10	47.84	49.82	52.12	53.70	5
idney	55	332,946	325	57.44	1.45	55.56	56.14	57.38	58.63	59.55	332,946	365	56.19	2.98	52.01	54.65	56.76	58.45	5
idney	60	299,441	396	62.51	1.46	60.54	61.16	62.50	63.76	64.56	299,441	445	60.82	3.56	55.83	59.08	61.77	63.62	6
laney	65	292,150	471	67.67	1.40	65.73	66.54	67.67	68.87	69.53	292,150	539	65.32	4.06	59.67	63.29	66.47	68.51	6
lladder	40	397,561	18	42.82	1.53	40.62	41.54	42.88	44.34	44.60	397,561	20	42.20	2.23	39.39	40.64	42.63	44.32	4
ladder	45	411,925	53	47.86	1.39	45.65	46.72	48.12	48.82	49.75	411,925	58	47.34	2.12	44.63	46.21	47.95	48.70	4
ladder	50	382,840	108	52.58	1.43	50.48	51.46	52.74	53.88	54.48	382,840	111	52.11	2.41	49.36	51.24	52.53	53.88	5
ladder	55	332,946	187	57.82	1.47	55.62	56.62	58.03	59.15	59.63	332,946	196	57.31	2.50	54.52	56.23	57.96	59.12	5
ladder	60	299,441	336	62.64	1.40	60.65	61.46	62.76	63.84	64.56	299,441	350	62.15	2.21	59.25	61.12	62.58	63.78	6
ladder	65	292,150	479	67.69	1.38	65.72	66.48	67.83	68.89	69.51	292,150	500	67.01	2.46	64.11	65.89	67.62	68.84	6
Irain	40	397,561	74	42.80	1.39	40.50	41.90	42.82	43.98	44.55	397,561	95	40.35	5.27	32.73	39.67	42.47	43.63	4
rain	45	411,925	121	47.58	1.36	45.71	46.60	47.43	48.79	49.53	411,925	138	45.14	5.64	37.92	44.35	47.02	48.59	4
rain	50	382,840	135	52.49	1.40	50.49	51.30	52.57	53.71	54.38	382,840	165	49.32	6.69	40.11	48.28	51.92	53.25	5
rain	55	332,946	171	57.59	1.36	55.63	56.45	57.55	58.78	59.57	332,946	204	53.89	7.67	43.83	53.13	56.92	58.22	5
rain	60	299,441	207	62.68	1.43	60.58	61.53	62.72	63.88	64.62	299,441	242	58.82	8.21	46.93	58.87	62.10	63.68	6
rain	65	292,150	242	67.71	1.51	65.66	66.32	67.74	69.09	69.74	292,150	289	63.35	8.83	51.06	63.38	66.32	68.60	6
HL	40	397,561	112	42.73	1.42	40.69	41.62	42.65	44.01	44.56	397,561	127	41.53	3.45	37.47	40.38	42.41	43.81	4
HL	45	411,925	173	47.92	1.33	46.02	46.78	48.07	49.11	49.57	411,925	184	46.97	3.21	43.95	46.06	47.87	49.00	4
IHL	50	382,840	234	52.62	1.45	50.68	51.35	52.69	53.93	54.65	382,849	253	51.50	3.17	47.93	50.03	52.28	53.80	5
HL	55	332,946	358	57.55	1.44	55.54	56.32	57.52	58.74	59.51	332,946	356	56.35	3.57	51.92	55.10	57.43	58.72	5
IHL	60	299,441	406	62.65	1.42	60.60	61.45	62.70	63.91	64.53	299,441	436	61.04	3.78	56.71	59.40	62.14	63.73	6
IHL	65	292,150	584	67.70	1.48	65.59	66.43	67.80	69.05	69.67	292,150	583	66.19	3.91	61.36	65.08	67.28	68.84	6
4M	40	397,561	24	43.10	1.44	41.07	42.01	43.10	44.56	44.65	397,561	27	42.60	1.98	39.70	41.63	43.01	44.44	4
4M	40	411,925	57	47.93	1.44	46.17	46.89	48.13	48.96	49.41	411,931	61	47.30	2.33	44.55	46.50	47.92	48.88	4
4M	50	382,840	106	52.91	1.28	50.92	46.89	48.13	48.96	54.63	382,840	100	52.62	2.53	50.71	46.50	53.07	48.88	5
4M		382,840	106	57.52	1.34	55.62	56.53	53.03	54.12	59.34		138	57.18	1.79	54.70	51.80	57.42	58.47	5
	55										332,946								
AM ANA	60	299,441	163	62.76	1.40	60.70	61.74	62.75	63.88	64.66	299,441	168	61.84	2.87	57.54	60.54	62.52	63.87	6
MM	65	292,150	278	67.73	1.36	65.77	66.55	67.82	68.87	69.57	292,150	302	66.73	3.13	63.76	65.99	67.48	68.72	65
ML	40	397,561	14	42.84	1.23	40.94	42.54	43.15	43.62	44.16	397,565	16	41.92	2.10	38.63	40.01	42.93	43.53	4
ML	45	411,925	24	48.06	1.07	46.40	47.38	48.14	48.90	49.21	411,925	22	47.13	2.46	43.31	46.83	47.93	48.87	4
ML	50	382,840	32	52.28	1.47	50.29	51.20	51.88	53.39	54.48	382,840	34	51.24	3.16	48.31	50.17	51.74	53.30	5
ML	55	332,946	40	57.84	1.57	55.39	56.73	58.08	59.36	59.71	332,946	45	56.36	3.89	51.76	55.16	57.50	59.04	5
ML	60	299,441	66	62.62	1.55	60.61	61.12	62.94	64.00	64.65	299,441	70	61.22	4.48	58.09	60.79	62.28	63.97	6
AML	65	292,150	99	67.76	1.48	65.65	66.42	67.93	69.00	69.75	292,151	104	66.36	4.76	63.43	65.78	67.69	68.90	6


Cancer	Age					Baselin	e				Population health informed screening								
	-	N	Cancers	Age - mean	Age - s.d.	Age - q10	Age - q25	Age - median	Age - q75	Age - q90	N	Cancers	Age - mean	Age - s.d.	Age - q10	Age - q25	Age - median	Age - q75	Age - q9
Oesophagus	55	67,266	24	57.93	1.36	55.98	56.85	58.21	58.85	59.69	67,266	27	56.84	2.62	52.58	55.67	57.54	58.79	59.66
Oesophagus	60	75,871	49	62.88	1.37	60.94	61.79	62.96	64.13	64.72	75,871	57	61.06	3.60	56.19	59.63	61.88	63.88	64.61
Oesophagus	65	98,019	93	67.64	1.43	65.48	66.55	67.63	68.88	69.38	98,019	101	65.23	4.13	60.13	63.04	66.55	68.21	69.30
Stomach	55	67,266	15	58.41	0.80	57.60	57.95	58.21	58.96	59.46	67,266	18	57.27	2.40	53.56	56.88	58.04	58.77	59.33
Stomach	60	75,871	37	62.72	1.54	60.46	61.55	62.63	64.13	64.73	75,871	40	62.13	2.23	59.08	60.46	62.29	64.00	64.66
Stomach	65	98,019	65	67.97	1.34	65.85	67.13	68.30	69.05	69.52	98,019	80	66.45	3.07	62.04	64.82	67.47	68.74	69.39
Colorectal	55	67,266	181	57.57	1.40	55.62	56.37	57.62	58.71	59.46	67,266	190	57.29	1.76	55.03	56.12	57.54	58.71	59.38
Colorectal	60	75,871	233	62.66	1.43	60.64	61.38	62.79	63.96	64.55	75,871	252	62.06	2.17	59.29	60.79	62.55	63.80	64.55
Colorectal	65	98,019	430	67.58	1.37	65.72	66.46	67.59	68.72	69.47	98,019	462	66.86	2.17	63.81	65.63	67.21	68.55	69.38
Liver	55	67,266	21	57.97	1.22	56.29	57.12	58.46	58.71	59.13	67,266	19	57.35	2.31	55.06	56.54	58.46	58.83	59.14
Liver	60	75,871	32	63.09	1.37	61.38	62.33	63.51	64.13	64.76	75,871	38	61.04	3.52	56.20	58.58	62.46	63.86	64.46
Liver	65	98,019	64	67.89	1.27	66.26	66.94	67.97	68.90	69.44	98,019	79	65.26	4.26	58.68	63.59	66.88	68.68	69.16
Pancreas	55	67,266	27	57.80	1.33	55.71	57.08	58.04	58.71	59.58	67,266	30	57.09	2.17	53.63	56.04	57.50	58.58	59.55
Pancreas	60	75,871	57	62.97	1.19	60.85	62.55	63.21	63.88	64.26	75,871	59	62.61	1.93	60.33	62.29	63.21	63.88	64.20
Pancreas	65	98,019	119	67.73	1.35	65.78	66.80	67.88	68.80	69.47	98,019	118	67.19	2.23	63.88	66.02	67.63	68.80	69.47
Lung	55	67,266	77	57.84	1.43	55.56	56.71	58.21	58.88	59.63	67,266	102	56.25	2.75	51.89	53.99	56.79	58.52	59.54
Lung	60	75,871	191	62.72	1.44	60.63	61.46	63.04	63.88	64.55	75,871	245	60.73	3.52	55.07	58.79	61.71	63.55	64.38
Lung	65	98.019	344	67.68	1.43	65.72	66.63	67.63	68.88	69.63	98.019	492	65.10	3.92	60.13	63.04	65.96	68.05	69.30
Breast	55	37,670	334	57.63	1.43	55.62	56.46	57.71	58.88	59.52	37,670	366	56.56	2.59	52.50	55.04	57.04	58.79	59.46
Breast	60	42,413	491	62.61	1.45	60.55	61.38	62.71	63.88	64.63	42,413	517	60.73	3.17	56.29	58.79	61.38	63.30	64.30
Breast	65	54,118	686	67.51	1.35	65.59	66.46	67.55	68.55	69.38	54,118	744	63.56	4.07	58.06	60.77	64.04	66.96	68.30
Corpus Uteri	55	37,670	56	57.51	1.44	55.63	56.12	57.46	58.81	59.42	37,670	65	56.63	2.19	53.54	55.21	56.62	58.54	59.34
Corpus Uteri	60	42,413	83	62.62	1.47	60.71	61.25	62.55	63.84	64.70	42,413	98	60.88	2.89	56.18	58.85	61.17	63.17	64.55
Corpus Uteri	65	54,118	110	67.54	1.47	65.71	66.63	67.63	68.47	69.47	54,118	144	64.77	3.88	58.69	62.52	65.67	67.88	68.83
Ovary	55	37,670	36	58.02	1.29	55.71	56.91	58.42	59.23	59.63	37,670	31	57.18	2.33	53.54	55.71	58.12	59.21	59.46
Ovary	60	42.413	59	62.82	1.41	60.94	61.67	62.71	64.21	64.73	42,413	52	62.15	2.33	59.06	60.75	62.59	64.09	64.79
	65	42,413	82	67.40	1.45	65.39	66.11	67.47	68.30	69.37	42,413	87	66.16	2.28	62.85	64.92	66.38	64.09	69.28
Ovary				57.75	1.39		56.54	57.88	59.04	59.63				1.77		56.37		59.04	
Prostate Prostate	55 60	29,596 33,458	212	62.82	1.47	55.46 60.71	61.71	62.88	64.04	64.72	29,596 33,458	222 397	57.50 62.32	2.10	54.87 59.38	61.21	57.75 62.71	63.96	59.63 64.66
Prostate	65	43,901	840	67.62	1.38	65.72	66.55	67.88	68.72	69.38	43,901	829	66.83	2.43	63.45	65.55	67.47	68.63	69.38
Kidney	55	67,266	31	57.71	1.56	55.54	56.46	57.79	59.08	59.79	67,266	35	57.06	2.23	54.29	55.50	57.46	58.96	59.79
Kidney	60	75,871	56	63.11	1.38	60.92	61.94	63.46	64.21	64.80	75,871	64	61.68	3.22	56.33	59.88	63.34	63.90	64.69
Kidney	65	98,019	127	67.76	1.29	65.82	66.96	67.88	68.76	69.47	98,019	118	66.69	2.85	63.38	65.36	67.55	68.70	69.41
Bladder	55	67,266	60	57.87	1.48	55.53	56.93	58.12	59.15	59.71	67,266	61	57.60	1.79	55.21	56.62	57.88	59.13	59.71
Bladder	60	75,871	85	62.75	1.41	60.66	61.71	62.71	64.04	64.68	75,871	95	62.12	2.12	59.58	60.75	62.55	63.84	64.60
Bladder	65	98,019	195	67.68	1.34	65.80	66.63	67.80	68.76	69.47	98,019	207	67.13	2.02	64.35	65.96	67.47	68.72	69.47
Brain	55	67,266	29	57.59	1.29	55.86	56.46	57.62	58.46	59.39	67,266	27	57.41	1.57	55.24	56.29	57.62	58.58	59.49
Brain	60	75,871	43	62.70	1.45	60.88	61.55	62.46	64.09	64.72	75,871	43	62.39	2.00	60.14	61.42	62.29	64.09	64.72
Brain	65	98,019	64	67.48	1.28	65.57	66.53	67.51	68.40	69.19	98,019	60	66.80	2.04	64.51	65.25	67.26	68.40	69.22
NHL	55	67,266	52	58.03	1.45	55.88	56.77	58.25	59.29	59.79	67,266	57	57.16	2.63	52.87	56.04	58.12	59.21	59.79
NHL	60	75,871	91	62.93	1.40	60.71	61.88	63.21	64.00	64.63	75,871	94	61.69	2.97	58.26	60.15	62.50	63.88	64.63
NHL	65	98,019	162	67.63	1.41	65.72	66.55	67.55	68.94	69.63	98,019	171	66.42	3.28	62.46	65.25	67.30	68.68	69.63
MM	55	67,266	29	57.37	1.34	55.46	56.29	57.54	58.37	59.39	67,266	28	57.40	1.38	55.36	56.42	57.58	58.39	59.40
MM	60	75,871	29	62.43	1.45	60.92	61.21	62.38	63.30	64.66	75,871	29	62.17	1.84	59.46	61.04	62.38	63.30	64.66
MM	65	98,019	98	67.61	1.40	65.52	66.57	67.72	68.70	69.49	98,019	92	67.29	2.14	65.04	66.53	67.72	68.70	69.54
AML	55	67,266	7	57.26	1.02	55.76	56.50	57.54	58.04	58.31	67,266	8	56.96	1.24	55.46	55.77	57.37	57.96	58.28
AML	60	75,871	13	62.68	1.31	60.89	62.29	62.71	63.55	64.26	75,871	15	62.03	2.06	59.09	60.92	62.71	63.42	64.15
AML	65	98,019	10	68.22	1.18	66.41	67.74	68.47	68.92	69.64	98,019	17	65.23	3.84	59.96	62.96	65.96	68.47	69.28

# ST7: Baseline risk comparison to Age-sex model on the UK Biobank

Cancer	Spearman Corr.	Pvalue	AUC Breslow	AUC UKB-AgeSex
Oesophagus	0.964	0.000	0.715	0.722
Stomach	0.986	0.000	0.682	0.687
Colorectal	0.991	0.000	0.639	0.640
Liver	0.977	0.000	0.701	0.701
Pancreas	0.991	0.000	0.657	0.660
Lung	0.968	0.000	0.668	0.673
Melanoma	0.836	0.000	0.577	0.591
Breast	0.615	0.000	0.535	0.547
Cervix Uteri	-0.777	0.000	0.472	0.513
Corpus Uteri	0.930	0.000	0.556	0.554
Ovary	0.995	0.000	0.575	0.576
Prostate	1.000	0.000	0.651	0.651
Testis	-0.494	0.000	0.528	0.509
Kidney	0.938	0.000	0.668	0.675
Bladder	0.998	0.000	0.751	0.751
Brain	0.969	0.000	0.588	0.594
Thyroid	0.734	0.000	0.620	0.663
Non-Hodgkin Lymphoma	0.959	0.000	0.629	0.634
Multiple Myeloma	0.981	0.000	0.659	0.662
AML	0.933	0.000	0.624	0.639
Other	0.993	0.000	0.652	0.654
Death	0.926	0.000	0.695	0.709

# **ST8:** Proportional hazards assumption for the overall predictor.

	Cancer	PH-Assumpt	ion Test
		Chi2 Statistic	P-value
	Oesophagus	13.091	0.000
	Stomach	10.060	0.002
	Colorectal	8.734	0.003
	Liver	0.833	0.361
	Pancreas	4.667	0.031
	Lung	0.317	0.573
	Melanoma	0.087	0.769
	Breast	1.433	0.231
	Cervix Uteri	0.319	0.572
	Corpus Uteri	2.875	0.090
ark	Ovary	0.875	0.350
Denmark	Prostate	121.108	0.000
De	Testis	1.310	0.252
	Kidney	12.333	0.252
	Bladder	2.121	0.000
	Brain	6.961	0.145
		0.040	0.008
	Thyroid Non-Hodgkin Lyr	5.575	0.041
	Multiple Myeloma		
		10.409	0.001
	AML	0.008	0.928
	Other	4.097	0.043
	Death	381.505	0.000
	Occorbogue	2.015	0.156
	Oesophagus Stomach	1.752	0.156
	Colorectal	0.436	0.180
	Liver	4.105	0.043
		0.007	0.043
	Pancreas	3.013	0.931
	Lung		
	Melanoma	0.056	0.813
	Breast		0.752
×	Cervix Uteri	0.004	0.949
UK Biobank	Corpus Uteri	2.324	0.127
<b>3iot</b>	Ovary	2.209	
Ϊ	Prostate		0.025
	Testis	0.494	0.482
	Kidney	3.881	0.049
	Bladder	0.012	0.912
	Brain	1.565	0.211
	Thyroid	1.297	0.255
	Non-Hodgkin Lyr	0.237	0.626
	Multiple Myeloma	0.697	0.404
	AML	2.888	0.089
	Other Death	0.985	0.321
		67.945	0.000



# SF1: Age-sex adjusted concordance for the development data.

Age-Sex adjusted Concordance


supplementary figure 1:

Concordance index for the development data on the Danish cohort.

# SFC-X: Summary plots


- a) Age-sex Incidence for the Danish and UKB cohort.
- b) Model estimates for underlying baseline risk.
- c) Forest plot based on HPD-90% coloured for significant effects based on HPD-95%. A maximum of 30 associations are shown.
- d) ROC-AUC curve and calibration plot for each decentile.
- e) Kaplan-Meier curve for the top 1% risk quantile between our predictions and an Age-Sex baseline for the Danish and UKB cohort.
- f) Lower/Upper quantiles of the 5-Year absolute risk as evaluated on the Danish and UKB cohort.

## SFC1: Oesophagus





### SFC2: Stomach

Stomach




# SFC3: Colorectal






#### SFC5: Pancreas



#### SFC6: Lung



## SFC7: Melanoma

At Risk: 42485 40058 42485 41380

43 77

Events: 0

37730 35713 40297 39457


84 133 150 218 At Risk: 3834 3780

Events: 0

3665 **3679** 

6 **8**  3510 3344 3610 3537

11 15 10 14




### SFC8: Breast


161 228

70 116


Events:  $\begin{array}{c} 0 \\ \textbf{0} \end{array}$ 




#### SFC9: Cervix Uteri




### SFC10: Corpus Uteri




## SFC11: Ovary




#### SFC12: Prostate







### SFC14: Kidney




## SFC15: Bladder




### SFC16: Brain




# SFC17: Thyroid



# SFC18: Non-hodgkin lymphoma



## SFC19: Multiple Myeloma



#### SFC20: AML

